Dr. Chih-Jung Chang is a distinguished researcher whose work spans microbiology, immunology, gut microbiota science, extracellular vesicles, and translational biotechnology, supported by an influential scholarly record comprising 4,163 citations, 47 documents, and an h-index of 22. His research consistently advances understanding of host–microbe interactions and the therapeutic potential of probiotics, prebiotics, microbial metabolites, and medicinal fungi in obesity, metabolic disorders, inflammation, and immune dysregulation. He has significantly contributed to unveiling mechanisms by which Ganoderma lucidum, Antrodia cinnamomea, and next-generation probiotics such as Parabacteroides goldsteinii mediate anti-obesity, anti-inflammatory, and immunomodulatory effects. His body of work includes high-impact publications in journals such as Nature Communications, Gut, Scientific Reports, International Journal of Obesity, Journal of Immunology, and Frontiers in Pharmacology, where he frequently appears as first author or corresponding author, demonstrating scientific leadership and editorial-level rigor. He has also pioneered research in extracellular vesicle–based diagnostics, identifying novel biomarkers for psoriasis, biliary tract infection, allergic rhinitis, cholecystitis, asthma, gestational diabetes, and related conditions through serum EV metagenomics, proteomics, and metabolomics. His multidisciplinary expertise is further reflected in studies on microbial signaling pathways, bacterial membrane vesicles, and immune regulation. Complementing his publication record, his innovative contributions are reinforced by multiple patents covering microbiota-derived therapeutics, anti-obesity polysaccharides, insulin-sensitizing compounds, and microbiome-modulating strategies. With an extensive research portfolio, consistent high-quality scholarly output, and strong innovation capacity, Chih-Jung Chang’s scientific achievements make him exceptionally well suited for the role of an Editorial Board Member.
Featured Publications
Lu, C.-W., Pang, J.-H. S., Ko, Y.-S., Chang, C.-J., Wang, C.-W., Chen, W.-T., Chen, C.-B., Hui, R. C.-Y., Hung, S.-I., & Lu, L.-Y. (2023). Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma. Journal of the European Academy of Dermatology and Venereology.
Wang, C.-W., Lin, W.-C., Chen, W.-T, Chen, C.-B., Lu, C.-W., Hou, H.-H., Hui, R. C.-Y., Wu, J., Chang, C.-J., & Chang, Y.-C. (2022). Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population. Frontiers in Pharmacology.
Lai, H.-C., Lin, T.-L., Chen, T.-W., Kuo, Y.-L., Chang, C.-J., Wu, T.-R., Shu, C.-C., Tsai, Y.-H., Swift, S., & Lu, C.-C. (2022). Gut microbiota modulates COPD pathogenesis: Role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide. Gut.
Wang, C.-W., Chi, M.-H., Tsai, T.-F., Yu, K.-H., Kao, H.-W., Chen, H.-C., Chen, C.-B., Lu, C.-W., Chen, W.-T., & Chang, Y.-C. (2022). Implementation of NUDT15 genotyping to prevent azathioprine-induced leukopenia for patients with autoimmune disorders in Chinese population. Clinical Pharmacology and Therapeutics.
Chiang, T.-Y., Yang, Y.-R., Zhuo, M.-Y., Yang, F., Zhang, Y.-F., Fu, C.-H., Lee, T.-J., Chung, W.-H., Chen, L., & Chang, C.-J. (2022). Microbiome profiling of nasal extracellular vesicles in patients with allergic rhinitis. World Allergy Organization Journal.